Polyomavirus BK and prostate cancer: An unworthy scientific effort?

Oncoscience

Volumn 1, Issue 4, 2014, Pages 296-303

  Delbue, Serena ^a   Ferrante, Pasquale ^a   Provenzano, Maurizio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

BKV DNA detection; Meta analysis; Polyomavirus BK; Prostate cancer

Indexed keywords

EID: 84925631477     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.35     Document Type: Article

References (71)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence. JAMA. 2014; 311: 1143-1149.
3. Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T. The role of genetic markers in the management of prostate cancer. Eur Urol. 2012; 62: 577-587.
4. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013; 63: 800-809.
5. Damaschke NA, Yang B, Bhusari S, Svaren JP, Jarrard DF. Epigenetic susceptibility factors for prostate cancer with aging. Prostate. 2013; 73: 1721-1730.
6. Ahmed A, Ali S, Sarkar FH. Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol. 2014; 229: 271-276.
7. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol. 1999; 155: 1985-1992.
8. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: The evidence. Histopathology. 2012; 60: 199-215.
9. Das D, Wojno K, Imperiale MJ. BK virus as a cofactor in the etiology of prostate cancer in its early stages. J Virol. 2008; 82: 2705-2714.
10. Delviks-Frankenberry K, Cingoz O, Coffin JM, Pathak VK. Recombinant origin, contamination, and de-discovery of XMRV. Curr Opin Virol. 2012; 2: 499-507.
11. Johne R, Buck CB, Allander T, Atwood WJ, Garcea RL, Imperiale MJ, Major EO, Ramqvist T, Norkin LC. Taxonomical developments in the family polyomaviridae. Arch Virol. 2011; 156: 1627-1634.
12. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003; 3: 611-623.
13. Comoli P, Hirsch HH, Ginevri F. Cellular immune responses to BK virus. Curr Opin Organ Transplant. 2008; 13: 569-574.
14. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009; 199: 837-846.
15. Turner DL, Gordon CL, Farber DL. Tissue-resident T cells, in situ immunity and transplantation. Immunol Rev. 2014; 258: 150-166.
16. Comoli P, Azzi A, Maccario R, Basso S, Botti G, Basile G, Fontana I, Labirio M, Cometa A, Poli F, Perfumo F, Locatelli F, Ginevri F. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation. 2004; 78: 1229-1232.
17. Comoli P, Binggeli S, Ginevri F, Hirsch HH. Polyomavirusassociated nephropathy: Update on BK virus-specific immunity. Transpl Infect Dis. 2006; 8: 86-94.
18. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: State of affairs. Transplantation. 2009; 87: 621-630.
19. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002; 347: 488-496.
20. Dalianis T, Hirsch HH. BK polyomavirus and transformation. In Cancer Associated Viruses (Erle S. Robertson Editor). 2012: 419-432.
21. Bergonzini V, Salata C, Calistri A, Parolin C, Palu G. View and review on viral oncology research. Infect Agent Cancer. 2010; 5: 11.
22. McLaughlin-Drubin ME, Meyers J, Munger K. Cancer associated human papillomaviruses. Curr Opin Virol. 2012; 2: 459-466.
23. Magrath I. Epidemiology: Clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012; 156: 744-756.
24. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002; 94: 1614-1619.
25. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol. 2002; 13: 1007-1015.
26. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008; 319: 1096-1100.
27. Brugge JS, Butel JS. Role of simian virus 40 gene a function in maintenance of transformation. J Virol. 1975; 15: 619-635.
28. Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol. 1993; 142: 1524-1533.
29. Topalis D, Andrei G, Snoeck R. The large tumor antigen: A "swiss army knife" protein possessing the functions required for the polyomavirus life cycle. Antiviral Res. 2013; 97: 122-136.
30. Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res. 2008; 68: 1022-1029.
31. Das D, Shah RB, Imperiale MJ. Detection and expression of human BK virus sequences in neoplastic prostate tissues. Oncogene. 2004; 23: 7031-7046.
32. Abend JR, Jiang M, Imperiale MJ. BK virus and human cancer: Innocent until proven guilty. Semin Cancer Biol. 2009; 19: 252-260.
33. Dayaram T, Marriott SJ. Effect of transforming viruses on molecular mechanisms associated with cancer. J Cell Physiol. 2008; 216: 309-314.
34. Cader FZ, Vockerodt M, Bose S, Nagy E, Brundler MA, Kearns P, Murray PG. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagenmediated activation of DDR1. Blood. 2013; 122: 4237-4245.
35. Ren C, Cheng X, Lu B, Yang G. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. Eur J Cancer. 2013; 49: 3889-3899.
36. Skinner GR. Transformation of primary hamster embryo fibroblasts by type 2 simplex virus: Evidence for a "hit and run" mechanism. Br J Exp Pathol. 1976; 57: 361-376.
37. Galloway DA, McDougall JK. The oncogenic potential of herpes simplex viruses: Evidence for a 'hit-and-run' mechanism. Nature. 1983; 302: 21-24.
38. Stevenson PG, May JS, Connor V, Efstathiou S. Vaccination against a hit-and-run viral cancer. J Gen Virol. 2010; 91: 2176-2185.
39. Dickmanns A, Zeitvogel A, Simmersbach F, Weber R, Arthur AK, Dehde S, Wildeman AG, Fanning E. The kinetics of simian virus 40-induced progression of quiescent cells into S phase depend on four independent functions of large T antigen. J Virol. 1994; 68: 5496-5508.
40. Gjoerup O, Chang Y. Update on human polyomaviruses and cancer. Adv Cancer Res. 2010; 106: 1-51.
41. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010; 463: 191-196.
42. Nevels M, Tauber B, Spruss T, Wolf H, Dobner T. "Hitand-run" transformation by adenovirus oncogenes. J Virol. 2001; 75: 3089-3094.
43. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7: 256-269.
44. Hrbacek J, Urban M, Hamsikova E, Tachezy R, Heracek J. Thirty years of research on infection and prostate cancer: No conclusive evidence for a link. A systematic review. Urol Oncol. 2013; 31: 951-965.
45. Siguier M, Sellier P, Bergmann JF. BK-virus infections: A literature review. Med Mal Infect. 2012; 42: 181-187.
46. Weinreb DB, Desman GT, Amolat-Apiado MJ, Burstein DE, Godbold JH, Jr., Johnson EM. Polyoma virus infection is a prominent risk factor for bladder carcinoma in immunocompetent individuals. Diagn Cytopathol. 2006; 34: 201-203.
47. Newton R, Ribeiro T, Alvarez E, Ziegler J, Casabonne D, Carpenter L, Beral V, Mbidde E, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Touze A, Coursaget P. BK virus and cancer in Uganda. Eur J Cancer Prev. 2006; 15: 285-289.
48. Newton R, Ribeiro T, Casabonne D, Alvarez E, Touze A, Key T, Coursaget P. Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort. Br J Cancer. 2005; 93: 1305-1306.
49. Shah KV, Daniel RW, Stone KR, Elliott AY. Investigation of human urogenital tract tumors of papovavirus etiology: Brief communication. J Natl Cancer Inst. 1978; 60: 579-582.
50. Fioriti D, Russo G, Mischitelli M, Anzivino E, Bellizzi A, Di Monaco F, Di Silverio F, Giordano A, Chiarini F, Pietropaolo V. A case of human polyomavirus BK infection in a patient affected by late stage prostate cancer: Could viral infection be correlated with cancer progression? Int J Immunopathol Pharmacol. 2007; 20: 405-411.
51. Weinreb DB. BK virus and carcinoma of the prostate, kidney and bladder. Br J Cancer. 2006; 94: 1948; author reply 1949-1950.
52. Wold WS, Mackey JK, Brackmann KH, Takemori N, Rigden P, Green M. Analysis of human tumors and human malignant cell lines for BK virus-specific DNA sequences. Proc Natl Acad Sci U S A. 1978; 75: 454-458.
53. May M, Kalisch R, Hoschke B, Juretzek T, Wagenlehner F, Brookman-Amissah S, Spivak I, Braun KP, Bar W, Helke C. [detection of papillomavirus DNA in the prostate: A virus with underestimated clinical relevance?]. Urologe A. 2008; 47: 846-852.
54. Delbue S, Matei DV, Carloni C, Pecchenini V, Carluccio S, Villani S, Tringali V, Brescia A, Ferrante P. Evidence supporting the association of polyomavirus BK genome with prostate cancer. Med Microbiol Immunol. 2013; 202: 425-430.
55. Monini P, Rotola A, Di Luca D, De Lellis L, Chiari E, Corallini A, Cassai E. DNA rearrangements impairing BK virus productive infection in urinary tract tumors. Virology. 1995; 214: 273-279.
56. Russo G, Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Giordano A, Autran-Gomez A, Di Monaco F, Di Silverio F, Sale P, Di Prospero L, Pietropaolo V. P53 gene mutational rate, gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation? J Med Virol. 2008; 80: 2100-2107.
57. Sais G, Wyler S, Hudolin T, Banzola I, Mengus C, Bubendorf L, Wild PJ, Hirsch HH, Sulser T, Spagnoli GC, Provenzano M. Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia. J Virol. 2012; 86: 8461-8471.
58. Groom HC, Warren AY, Neal DE, Bishop KN. No evidence for infection of UK prostate cancer patients with XMRV, BK virus, trichomonas vaginalis or human papilloma viruses. PLoS One. 2012; 7: e34221.
59. Bergh J, Marklund I, Gustavsson C, Wiklund F, Gronberg H, Allard A, Alexeyev O, Elgh F. No link between viral findings in the prostate and subsequent cancer development. Br J Cancer. 2007; 96: 137-139.
60. Balis V, Sourvinos G, Soulitzis N, Giannikaki E, Sofras F, Spandidos DA. Prevalence of BK virus and human papillomavirus in human prostate cancer. Int J Biol Markers. 2007; 22: 245-251.
61. Akgul B, Pfister D, Knuchel R, Heidenreich A, Wieland U, Pfister H. No evidence for a role of xenotropic murine leukaemia virus-related virus and BK virus in prostate cancer of german patients. Med Microbiol Immunol. 2012; 201: 245-248.
62. Lau SK, Lacey SF, Chen YY, Chen WG, Weiss LM. Low frequency of BK virus in prostatic adenocarcinomas. APMIS. 2007; 115: 743-749.
63. Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate. 2008; 68: 306-320.
64. Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate. 2002; 53: 263-276.
65. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, Johnson-Pais T, Beuten J, Morales-Rodriguez IB, Hernandez-Ordonez MA, Calderon-Cardenas G, Ortiz-Lopez R, Rivas-Estilla AM, Ancer-Rodriguez J, Rojas-Martinez A. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer. 2010; 10: 326.
66. Zhong S, Suzuki M, Peng X, Shen ZJ, Wang XJ, Xu TY, Li T, Yogo Y, Homma Y. BK polyomavirus from patients with tissue-derived prostate adenocarcinoma. Future Virology. 2013; 8: 313-320.
67. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: A systematic review. Eur Urol. 2014; in press.
68. Schlomm T, Erbersdobler A, Mirlacher M, Sauter G. Molecular staging of prostate cancer in the year 2007. World J Urol. 2007; 25: 19-30.
69. Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: Genomic alterations and heterogeneity. Nat Rev Urol. 2012; 9: 652-664.
70. De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol. 2007; 25: 398-400.
71. Grizzle WE, Srivastava S, Manne U. The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark. 2010; 9: 21-39.